UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-028	7			
Estimated average burden					
nours per response	e 0.	5			

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)													
1. Name and Address of Reporting Person * Scibetta James S			2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302				3. Date of Earliest Transaction (Month/Day/Year) 03/30/2018							r (give title belo		Other (specify b	elow)	
(Street) BEDMINSTER, NJ 07921				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
(Instr. 3) Date		Date (Month/Day/Year)	2A. Deemed Execution Date, if		(Instr. 8)		-		quired of	d 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		ies Following	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
						Cod	e V	Amoui	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common	Stock		03/30/2018			A		24,672 (1)	2 A	\$ 0	442,981			D	
			Table II - De	erivative Seg., puts, cal			cont the f	ained in orm dis sposed o	n this for splays a of, or Ben	rm ar curre	e not req ently valid lly Owned	uired to re	nformation espond unl ntrol numb	ess	EC 1474 (9- 02)
	2. 3. Transacti Conversion Date or Exercise Price of Derivative Security		on 3A. Deemed Execution Dat	4. Transaction Code Year) (Instr. 8)		5. Number 6. I of and		Jate Exercisable I Expiration Date onth/Day/Year)		7. T Ame Und Seco	ritle and ount of derlying urities tr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownersh Form of Derivativ Security Direct (I or Indire	Beneficial Ownership (Instr. 4)
				Code	v	(A) (I		cisable	Expiration Date	n Title	Amount or Number of Shares				
Repor	ting O	wners	,			·					•			'	,
Reporting Owner Name / Address				Relationships											
Scibetta J		cr rimile /		Director	10%	Owner	Office	r Other	-						
ocioetta J	ailles 3														

Reporting Owner Name / Address		Relationships					
		10% Owner	Officer	Other			
Scibetta James S C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER, NJ 07921	Х						

Signatures

/s/ Jerome D. Jabbour, attorney-in fact for James S. Scibetta	04/02/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On March 30, 2018, the Reporting Person was issued 24,672 shares of common stock par value \$.0001 per share which vest immediately upon grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

